Clinical symptoms of SARS‐CoV‐2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination—A prospective multicentre cohort of health professionals (SURPRISE study)

The effects of different types of pre‐existing immunity on the frequency of clinical symptoms caused by the SARS‐CoV‐2 breakthrough infection were prospectively assessed in healthcare workers during the Omicron period. Among 518 participants, hybrid immunity was associated with symptom reduction for...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Influenza and other respiratory viruses 2023-06, Vol.17 (6), p.e13167-n/a
Hauptverfasser: Kohler, Philipp, Babouee Flury, Baharak, Güsewell, Sabine, Egger, Thomas, Leal, Onicio, Brucher, Angela, Lemmenmeier, Eva, Meier Kleeb, Dorette, Möller, J. Carsten, Ortner, Manuela, Rieder, Philip, Ruetti, Markus, Schmid, Hans‐Ruedi, Stocker, Reto, Vuichard‐Gysin, Danielle, Speer, Oliver, Wiggli, Benedikt, Besold, Ulrike, McGeer, Allison, Risch, Lorenz, Friedl, Andrée, Schlegel, Matthias, Vernazza, Pietro, Kahlert, Christian R., Kuster, Stefan P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The effects of different types of pre‐existing immunity on the frequency of clinical symptoms caused by the SARS‐CoV‐2 breakthrough infection were prospectively assessed in healthcare workers during the Omicron period. Among 518 participants, hybrid immunity was associated with symptom reduction for dizziness, muscle or limb pain and headache as compared to vaccination only. Moreover, the frequencies of dizziness, cough and muscle or limb pain were lower in participants who had received a booster vaccine dose. Thus, hybrid immunity appeared to be superior in preventing specific symptoms during breakthrough infection compared to vaccination alone. A booster vaccine dose conferred additional symptom reduction.
ISSN:1750-2640
1750-2659
1750-2659
DOI:10.1111/irv.13167